301301Chuanning BiotechnologySZSE

Yili Chuannig Biotechnology Co., Ltd.

川宁生物

301301

Shenzhen Stock Exchange

BoardChiNext of Shenzhen Stock Exchange
IndustryPharmaceutical Manufacturing
ListedDecember 27, 2022
Websitewww.klcnsw.com
IR Emailir@klcnsw.com
Phone(+86)0999-8077567
AddressNo.1 Gongchen Road, Yining Park, Horgos Economic Development Zone, Ili Kazakh Autonomous Prefecture, Xinjiang

Company Profile

(A) Resource and cost advantages The company makes full use of the advantages of geography, resources and location in Yili, Xinjiang, and reduces the production cost from multiple dimensions, so that the company's products have more cost advantages in the fierce market competition. 1. Climate: The company is located in the Ili River Valley, where there are climatic conditions such as temperature and humidity suitable for biological fermentation, which can improve the fermentation level and further reduce the production cost of the company. 2. Raw materials: The company is located near the corn production area, with sufficient sunlight and high corn protein content. The overall production cost is relatively lower than that of mainland production enterprises, and the price of corn is more than 20% cheaper than that of the mainland. 3. Initiative: The company has a coal-fired power plant and is close to the coal producing area, and the cost of coal and energy in Xinjiang is relatively low. The company has obvious advantages in energy cost, which is more than 50% cheaper than that in the mainland. 4. Location: The Horgos Economic Development Zone, where the company is located, is the core area of the national development strategy of "the belt and road initiative" and "Silk Road". The company can purchase raw materials needed for production from abroad through cross-border trade, further reducing the company's operating costs. At the same time, the company currently enjoys the preferential tax policy of "five exemptions and five reductions" in the Horgos Special Economic Zone. (B) environmental advantages Chuanning Bio has always adhered to the strategy of "giving priority to environmental protection and sustainable development" and the concept of "setting an environmental protection model for the global antibiotic industry". The total investment of environmental protection facilities exceeds 2.7 billion yuan, accounting for more than 30% of the total investment of the project. The environmental protection system covers an area of more than 300 mu, accounting for more than 20% of the total area of the factory. Advanced key technologies and equipment such as molecular sieve, hydrophobic activated carbon, MVR, special membrane and spray drying have been introduced at home and abroad successively, which has solved the problem of environmental protection "three wastes" treatment, and the treatment capacity of wastewater, waste gas and waste residue has reached advanced level. 1. Fermentation tail gas treatment field: High-end integrated technologies such as "imported molecular sieve runner, hydrophobic activated carbon bed and high-temperature thermal oxidation" have been adopted, which makes all indicators of the odor treatment system of biological fermentation tail gas in Chuanning normal and stable, and the removal rate remains above 95%. 2. Waste water treatment field: A number of technologies such as "MVR evaporation" and "ultrafiltration +DTNF+DTRO" combined membrane filtration advanced treatment have been adopted, and more than 80% of the treated waste water can be reused for circulating cooling water, pre-production process water, thermoelectric boiler water, etc., thus realizing the recycling of waste water and saving primary water resources. 3. In the field of bacterial residue treatment, the advanced technology of "DD high-voltage electron radiation" and "high-temperature hydrolysis+spray drying/disc drying" for antibiotic bacterial residue was adopted, and the harmless treatment of bacterial residue was used as the raw material for producing organic fertilizer, thus realizing resource recycling. Therefore, with the approval of the Ministry of Ecology and Environment in January 2018, Chuanning Bio established the "National Engineering Technology Center for Harmless Treatment and Resource Utilization of Antibiotic Residues for Environmental Protection", which passed the acceptance of Xinjiang Uygur Autonomous Region and the Ministry of Ecology and Environment in November 2020 and January 2021 respectively. In January 2023, the fertilizer made from the company's antibiotic residue was exempted from certification in Xinjiang, allowing the fertilizer made from antibiotic residue to be used for planting crops in Xinjiang, and the planted crops were not allowed to enter the food chain. (C) technological innovation advantages Technological innovation of synthetic biology: The company completed the engineering closed loop of strain design, construction, testing and learning through ab initio calculation design, automatic high-throughput strain construction and screening, multi-scale fermentation process optimization, big data analysis and machine learning. Through several rounds of iteration, it "intelligently created" engineering strains with excellent performance and suitable for industrial production. This process overcame the limitations of traditional biological breeding and greatly improved the research and development efficiency. Technological innovation of biological fermentation: Through independent innovation, technology introduction and technology integration, the company has achieved many breakthroughs in core technologies, key links and key areas. The original 500 m fermentor of Chuanning Bio-technology is the largest fermentor of antibiotics in the world at present, and the output and efficiency of single batch are greatly improved, and the scale benefit is remarkable. The company paid attention to innovation investment, solved the "stuck neck" problem, took the lead in breaking foreign technical barriers and became the first enterprise in China to produce 7-ADCA products by enzymatic method. The new technology greatly reduced the production cost and improved the company's economic benefits. (D) Advantages of scale production The company has a wide range of fermentation and extraction equipment, and can switch to produce different kinds of products. The company is one of the leading enterprises in the field of antibiotic intermediates, with complete product types and leading production technology. The products sold include erythromycin thiocyanate, 6-APA, 7-ACA and penicillin G potassium salt, covering the main intermediates of macrolides and broad-spectrum antibiotics. The company's original 500 m fermentor is the largest fermentor for antibiotics in the world at present, which greatly improves the output and efficiency of a single batch and has remarkable scale benefits. (E) circular advantages of green economy The fungus residue produced in the fermentation production process of the company effectively eliminates harmful factors such as antibiotic residues in the fungus residue and adverse environmental effects through strict harmless disposal technology. The organic fertilizer produced after disposal is used for directional planting of industrial corn, soybeans and other crops, and all the harvested corn, soybeans and other crops are reused in the fermentation production process of the company's products. Form a new closed-loop harmless resource treatment model for the whole process supervision of the competent department of ecological environment and all walks of life, and control the risk, and establish a green circular economy industrial supply chain system that combines modern pharmaceutical manufacturing and modern agriculture, so as to realize the harmless treatment and efficient resource utilization of bacterial residues.

Full description

The company belongs to the pharmaceutical manufacturing industry, located in Khorgos Economic Development Zone, which is the core area of the Silk Road Economic Belt of the national "the belt and road initiative" development strategy, and is mainly engaged in the research and development and industrialization of bio-fermentation technology. The project covers an area of 1,319 mu, with a total investment of over 8 billion yuan. There are one erythromycin thiocyanate production line, two cephalosporin series intermediates production lines and one ursodeoxycholic acid crude product production line, with a total production capacity of about 16,000 tons/year. The main products include erythromycin thiocyanate, cephalosporin intermediates (7-ACA, 7-ADCA, D-7ACA) and penicillin intermediates. Among the main products currently produced by the company, erythromycin thiocyanate is mainly used to further synthesize macrolide antibiotics, such as erythromycin, roxithromycin and azithromycin. 7-ACA, D-7AA and 7-ADCA are mainly used to synthesize cephalosporin drugs. Potassium salts of 6-APA and penicillin G are mainly used to synthesize penicillin antibiotics. Ursodeoxycholic acid (crude product) is mainly used for refining ursodeoxycholic acid; Coenzyme Q10 mycelium is mainly used to produce coenzyme Q10.

Announcements

0 shown